Clinical trials: Advanced Tumor
Metastatic Castration-Resistant Prostate Cancer
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
This is a phase II study which will test the study drug MLN0128 in patients with castration resistant prostate cancer who have received chemotherapy in the past.
- Trial name
- NCT02091531
- Testing
- MLN0128
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Phase 2, Zanzalintinib
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
To learn if zanzalintinib and pembrolizumab can help to control select subtypes of advanced/metastatic soft-tissue sarcoma (UPS, MFS, HGPS, and HGUS
- Conditions
- Phase 2, Zanzalintinib, Pembrolizumab, Advanced/Metastatic
- Trial name
- NCT07283731
- Testing
- Zanzalintinib, Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
NSCLC (Advanced Non-small Cell Lung Cancer)
Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
This clinical trial consists of two parts: phase 2 and phase 3. The goal of phase 2 of this clinical trial is to compare which dose level of AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype…
- Trial name
- NCT07718737
- Testing
- AMT-116, Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab)
- Where
- 7 sites in United States, Australia
- Volunteers
- 512 people
- Sponsor
- Multitude Therapeutics Inc.
Medullary Thyroid Cancer
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that…
- Trial name
- LIBRETTO-531 (NCT04211337)
- Testing
- Selpercatinib, Cabozantinib, Vandetanib
- Where
- 143 sites in United States, Australia and 18 more
- Volunteers
- 291 people
- Sponsor
- Loxo Oncology, Inc.
Advanced Malignant Solid Tumor
YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases
The preclinical pharmacological mechanism of YH02 injection is well established. By constructing a vector expressing MMP13, introducing a human S promoter, and genetically modifying the capsid protein, the virus's permeability…
- Trial name
- YH02 (NCT07697937)
- Testing
- YH-02
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin First Central Hospital
Advanced Malignant Tumours
Clinical Trial to Evaluate the Tolerance of TQB2210 Injection
TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity and inhibit tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor.
- Trial name
- NCT06929195
- Testing
- TQB2210 Injection
- Where
- 7 sites in China
- Volunteers
- 16 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin, and cyclophosphamide, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00074139
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Locally Advanced Solid Tumor, Metastatic Cancer
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer
- Trial name
- NCT04319757
- Testing
- ACE1702, Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 12 people
- Sponsor
- Acepodia Biotech, Inc.
Ovarian Cancer, Peritoneal Cavity Cancer
Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00825201
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, liquid chromatography, mass spectrometry
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Neoplasms
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
This Phase Ib, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of the combination of MOXR0916 and atezolizumab in participants with locally advanced, recurrent, or metastatic…
- Trial name
- NCT02410512
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 610 people
- Sponsor
- Genentech, Inc.
Ovarian Cancer, Fatigue
REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue
This study is testing whether a 6 week skills-based telehealth intervention can help ovarian cancer patients experiencing PARP inhibitor-related fatigue reduce the impact of fatigue on their daily life and activities.
- Conditions
- Ovarian Cancer, Fatigue, Coping Behavior, Coping Skills
- Trial name
- NCT04525183
- Testing
- Enhanced Usual Care (EOC), REVITALIZE ACT Intervention
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Non Small Cell Lung Cancer
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
This study evaluates Navtemadlin (KRT-232) in combination with Pembrolizumab as a maintenance therapy in patients with locally advanced and metastatic non small cell lung cancer.
- Trial name
- NCT05705466
- Testing
- Navtemadlin, Pembrolizumab
- Sponsor
- Kartos Therapeutics, Inc.
Non-Small-Cell Lung Cancer
Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)
This is a two-arm, parallel, open-label, Phase 2 multicenter study of pemetrexed as first line combination therapy with either cisplatin or carboplatin in the palliative setting of stage IIIb and IV non-small cell lung cancer…
- Trial name
- NCT00402051
- Testing
- Pemetrexed, Cisplatin, Carboplatin
- Where
- 12 sites in Germany
- Volunteers
- 133 people
- Sponsor
- Eli Lilly and Company
ER Positive, HER2 Negative Breast Cancer Neoplasms
Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer
A prospective, non-interventional, non-controlled multicenter observational study to evaluate aspects of pharmaceutical care and the treatment of postmenopausal patients with hormone-receptor positive, HER2-receptor negative…
- Trial name
- IPSOC-mamma (NCT02875951)
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- KU Leuven
Lung Cancer
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin are more effective with or without BMS-275291 for…
- Trial name
- NCT00006229
- Testing
- carboplatin, paclitaxel, rebimastat
- Where
- 69 sites in United States, Austria and 12 more
- Volunteers
- 774 people
- Sponsor
- NCIC Clinical Trials Group
Ovarian Cancer, Sexual Function
Advanced Ovarian Cancer and Sexuality Phase 1
Women with Advanced Ovarian Cancer (AOC) suffer from severe sexual side effects from treatment. The prevalence of the sexual issues is not known.
- Trial name
- ANOVA1 (NCT00488202)
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- University of British Columbia
Advanced Bladder Cancer
The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer
The goal of this clinical trial is to learn if the timing of treatments plays a role in how effective the standard-of-care drugs enfortumab vedotin and pembrolizumab (EV/P) works to treat adults with advanced bladder cancer.
- Trial name
- Chrono-EVP (NCT07346053)
- Testing
- enfortumab vedotin and pembrolizumab (EV/P)
- Where
- 5 sites in Canada
- Volunteers
- 224 people
- Sponsor
- Guliz Ozgun
Oesophageal Cancer, Gastro-Oesophageal Junction Cancer
A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer
SOlar is a multi-centre phase II clinical trial of single agent olaparib in advanced oesophagogastric cancer.
- Conditions
- Oesophageal Cancer, Gastro-Oesophageal Junction Cancer, Gastric Cancer
- Trial name
- SOLAR (NCT03829345)
- Testing
- Olaparib
- Where
- 2 sites in United Kingdom
- Volunteers
- 54 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer, Colorectal Cancer
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma
- Trial name
- STARLING (NCT05576077)
- Testing
- TBio-4101, Pembrolizumab
- Where
- 13 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Turnstone Biologics, Corp.
Prostatic Neoplasms
Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer
This prospective, open randomized phase III surgical trial seeks to study whether radical prostatectomy (with or without the combination of external radiation) improves prostate-cancer specific survival in comparison with primary…
- Trial name
- SPCG-15 (NCT02102477)
- Testing
- Prostatectomy/Surgery, Radiotherapy with adjuvant androgen deprivation therapy
- Where
- 30 sites in Denmark, Finland and 2 more
- Volunteers
- 1,200 people
- Sponsor
- Olof Akre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.